Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression

Author(s): Lynn R. Webster*, Erik Hansen, Gregory J. Stoddard, Austin Rynders, David Ostler and Harley Lennon

Volume 17, Issue 1, 2022

Published on: 24 February, 2021

Page: [72 - 80] Pages: 9

DOI: 10.2174/1574884716666210225083213

Price: $65

Abstract

Background: Opioid analgesics used to treat pain can cause respiratory depression. However, this effect has not been extensively studied, and life-threatening, opioid-induced respiratory depression remains difficult to predict. We tested the ventilatory response to hypercapnia for evaluating the pharmacodynamic effect of a drug on respiratory depression.

Methods: We conducted a randomized, placebo-controlled, double-blind, crossover study on 12 healthy adult males. Subjects received 2 treatments (placebo and immediate-release oxycodone 30 mg) separated by a 24-hour washout period. Subjects inhaled a mixture of 7% carbon dioxide, 21% oxygen, and 72% nitrogen for 5 minutes to assess respiratory depression. Minute ventilation, respiratory rate, tidal volume, flow rate, end-tidal CO2, and oxygen saturation were recorded continuously at pre-dose and 30, 60, 120, and 180 minutes post-dose. The primary endpoint was the effect on the ventilatory response to hypercapnia at 60 minutes post-dose, as assessed by the slope of the linear relationship between minute ventilation and end-tidal CO2.

Results: At 60 minutes post-dose, subjects had a mean slope of 2.4 in the oxycodone crossover period, compared to 0.1 in the placebo period (mean difference, 2.3; 95% CI: 0.2 to 4.5; p = 0.035). Statistical significance was likewise achieved at the secondary time points (30, 120, and 180 minutes post-dose, p <0.05).

Conclusions: This model for testing ventilatory response to hypercapnia discriminated the effect of 30 mg of oxycodone vs. placebo for up to 3 hours after a single dose. It may serve as a method to predict the relative effect of a drug on respiratory depression.

Keywords: Ventilatory response, hypercapnia, respiratory depression, experimental model, opioids, analgesics.

« Previous
Graphical Abstract

[1]
National Institute on Drug Abuse. Overdose Death Rates 2019. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (Accessed January 6, 2021).
[2]
World Health Organization. Information sheet on opioid overdose: key facts 2018. Available from: https://www.who.int/substance_abuse/information-sheet/en/ (Accessed January 6, 2021).
[3]
Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010; 112(1): 226-38.
[http://dx.doi.org/10.1097/ALN.0b013e3181c38c25] [PMID: 20010421]
[4]
Fecho K, Jackson F, Smith F, Overdyk FJ. In-hospital resuscitation: opioids and other factors influencing survival. Ther Clin Risk Manag 2009; 5: 961-8.
[http://dx.doi.org/10.2147/TCRM.S8121] [PMID: 20057895]
[5]
Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015; 175(4): 608-15.
[http://dx.doi.org/10.1001/jamainternmed.2014.8071] [PMID: 25686208]
[6]
Zedler B, Xie L, Wang L, et al. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans’ Health Administration patients. Pain Med 2015; 16(8): 1566-79.
[http://dx.doi.org/10.1111/pme.12777] [PMID: 26077738]
[7]
Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med 2018; 19(1): 68-78.
[http://dx.doi.org/10.1093/pm/pnx009] [PMID: 28340046]
[8]
Dahan A, Overdyk F, Smith T, Aarts L, Niesters M. Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients. Pain Physician 2013; 16(2): E85-94.
[PMID: 23511694]
[9]
Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg 2017; 125(5): 1741-8.
[http://dx.doi.org/10.1213/ANE.0000000000002496] [PMID: 29049118]
[10]
Binswanger IA, Stern MF, Deyo RA, et al. Release from prison-a high risk of death for former inmates. N Engl J Med 2007; 356(2): 157-65.
[http://dx.doi.org/10.1056/NEJMsa064115] [PMID: 17215533]
[11]
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 2014; 81(3): 14-8.
[PMID: 25951678]
[12]
Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur 1998; 6(2): 65-74.
[http://dx.doi.org/10.1080/105294199277860] [PMID: 10386329]
[13]
Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001; 54(4): 343-9.
[http://dx.doi.org/10.1016/S0895-4356(00)00314-0] [PMID: 11297884]
[14]
Metcalfe C. The analysis of cross-over trials with baseline measurements. Stat Med 2010; 29(30): 3211-8.
[http://dx.doi.org/10.1002/sim.3998] [PMID: 21170915]
[15]
U.S. Food and Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use 2016. Available from: https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine (Accessed January 6, 2021).
[16]
Warner M, Trinidad JP, Bastian BA, Minino AM, Hedegaard H. Drugs most frequently involved in drug overdose deaths: United States, 2010-2014. Natl Vital Stat Rep 2016; 65(10): 1-15.
[PMID: 27996932]
[17]
Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 1975; 292(21): 1103-6.
[http://dx.doi.org/10.1056/NEJM197505222922106] [PMID: 1128555]
[18]
van der Schrier R, Jonkman K, van Velzen M, et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br J Anaesth 2017; 119(6): 1169-77.
[http://dx.doi.org/10.1093/bja/aex295] [PMID: 29029015]
[19]
Oertel BG, Schneider A, Rohrbacher M, et al. The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans. Clin Pharmacol Ther 2007; 81(1): 59-68.
[http://dx.doi.org/10.1038/sj.clpt.6100018] [PMID: 17186000]
[20]
Oertel BG, Felden L, Tran PV, et al. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Clin Pharmacol Ther 2010; 87(2): 204-11.
[http://dx.doi.org/10.1038/clpt.2009.194] [PMID: 19907420]
[21]
Leino K, Mildh L, Lertola K, Seppälä T, Kirvelä O. Time course of changes in breathing pattern in morphine- and oxycodone-induced respiratory depression. Anaesthesia 1999; 54(9): 835-40.
[http://dx.doi.org/10.1046/j.1365-2044.1999.00946.x] [PMID: 10460553]
[22]
Centers for Disease Control and Prevention. Calculating Total Daily Dose of Opioids for Safer Dosage Available from: https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf (Accessed January 6, 2021).
[23]
van der Schrier R, Roozekrans M, Olofsen E, et al. Influence of ethanol on oxycodone-induced respiratory depression: a dose-escalating study in young and elderly individuals. Anesthesiology 2017; 126(3): 534-42.
[http://dx.doi.org/10.1097/ALN.0000000000001505] [PMID: 28170358]
[24]
Chang SH, Maney KM, Phillips JP, Langford RM, Mehta V. A comparison of the respiratory effects of oxycodone versus morphine: a randomised, double-blind, placebo-controlled investigation. Anaesthesia 2010; 65(10): 1007-12.
[http://dx.doi.org/10.1111/j.1365-2044.2010.06498.x] [PMID: 20712805]
[25]
Webster L, Schmidt WK. Dilemma of addiction and respiratory depression in the treatment of pain: a prototypical endomorphin as a new approach. Pain Med 2020; 21(5): 992-1004.
[http://dx.doi.org/10.1093/pm/pnz122] [PMID: 31165885]
[26]
Majumdar S, Grinnell S, Le Rouzic V, et al. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA 2011; 108(49): 19778-83.
[http://dx.doi.org/10.1073/pnas.1115231108] [PMID: 22106286]
[27]
Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 2017; 171(5): 1165-1175.e13.
[http://dx.doi.org/10.1016/j.cell.2017.10.035] [PMID: 29149605]
[28]
Phoenix PharmaLabs. Technology 2018. Available from: https://phoenixpharmalabs.com/technology/ (Accessed January 6, 2021).

Rights & Permissions Print Cite
Article Metrics
30
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy